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ORIGINAL INVESTIGATION
No detectable differential microRNA 
expression between non-atherosclerotic arteries 
of type 2 diabetic patients (treated or untreated 
with metformin) and non-diabetic patients
Lasse Bach Steffensen1,2,3,4*† , Søren Feddersen1,3†, Simone Rørdam Preil1,2 and Lars Melholt Rasmussen1,2,3
Abstract 
Background: Type 2 diabetes mellitus (T2DM) is an independent risk factor of cardiovascular disease (CVD), however, 
the underlying mechanisms are largely unknown. Using non-atherosclerotic internal thoracic arteries (ITAs) obtained 
from coronary artery bypass grafting, we previously identified a distinct elevation in the level of proteins comprising 
the arterial basement membrane in T2DM patients not treated with metformin. Altered transcription of genes encod-
ing these proteins has not been observed, indicating alternative mechanisms of dysregulation.
Methods: In this study we screened for differential expression of arterial microRNAs (miRNAs) in T2DM patients 
to test the hypothesis that the arterial protein signature of diabetic patients is associated with dysregulation at the 
miRNA level, and further to lay the foundation for novel hypotheses addressing the increased CVD risk of T2DM 
patients. MiRNA isolated from fresh frozen ITAs [from 18 T2DM- (10 of which were subject to metformin treatment) 
and 30 non-diabetes mellitus (non-DM) patients] were analyzed by microarray, and miRNAs isolated from formalin-
fixated paraffin-embedded (FFPE) ITAs were analyzed by quantitative PCR (qPCR) in an independent study group [26 
T2DM- (15 of which were subject to metformin treatment) and 26 non-DM patients] to determine expression levels of 
miRNAs in a pre-defined panel of 12 miRNAs.
Results: Unexpectedly, no miRNAs were found to be affected by T2DM status in either of the two study groups.
Conclusions: Our data suggest that alternatives to microRNA dysregulation underlie T2DM-associated protein 
changes in non-atherosclerotic arteries.
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Background
Diabetic patients have increased morbidity and mor-
tality of cardiovascular disease (CVD) including stroke 
and acute myocardial infarction [1]. The underlying 
mechanisms are far from understood, however, CVD 
risk in diabetic patients is independent of hyperlipi-
demia and hypertension [2] suggesting a direct effect of 
hyperglycemia and/or insulin resistance within macro-
vascular tissue. This idea is supported by studies showing 
that diabetic patients have altered remodeling capacity 
[3, 4] as well as an augmented prevalence of artery cal-
cification [5] and -stiffening [6]. A paradoxical protec-
tion against aneurysms among diabetic individuals is 
likewise compatible with the notion that specific arte-
rial alterations form the background for cardiovascular 
consequences of diabetes [7]. Our group previously pro-
vided additional support for a direct effect of diabetes in 
arterial tissue by demonstrating that a distinct group of 
proteins constituting the vascular basement membrane 
(including the α1- and α2-chains of collagen IV, as well as 
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ɣ1-laminin and β2-laminin) was elevated in arteries from 
diabetic patients (40 and 20% for the α1- and α2-chains 
of collagen IV, respectively) [8]. Diabetic patients treated 
with metformin, a standard drug with beneficial effects 
on glucose metabolism and diabetes-related complica-
tions [9], had significantly reduced levels of these pro-
teins as compared to non-metformin treated diabetic 
patients [8]. Interestingly, these protein alterations do not 
appear to be accompanied by changes of the correspond-
ing gene transcripts [10, 11]. This indicates alternative 
mechanisms of the observed diabetes-induced effects at 
the protein level, such as reduced protein degradation 
(possibly as a consequence of protein glycation or oxida-
tive modifications) and/or altered expression of epige-
netic regulators of messenger RNA (mRNA) translation. 
Especially the idea of microRNA (miRNA)-mediated 
epigenetic regulation is appealing since COL4A1 and 
COL4A2 mRNA (encoding the α1- and α2-chain of col-
lagen IV, respectively) are subject to pronounced regula-
tion by miRNAs miR-29a and miR-29b [12–17], which 
are expressed in vascular tissue [18].
MiRNAs are short (~ 22 nucleotides) single-stranded 
non-coding RNA molecules that bind to target mRNA 
mainly in 3′ untranslated regions causing transla-
tion blockade or mRNA cleavage thereby resulting in 
decreased translation [19]. Only the former would be 
detectable by transcriptomic approaches.
Studies investigating miRNA expression in vascular 
tissue are scant, and to our knowledge, an explorative 
approach has ever been used to assess the effect of type 2 
diabetes mellitus (T2DM) on miRNA expression in non-
lesional arteries. We therefore sought to screen for differ-
entially expressed miRNAs by microarray analysis to test 
the hypothesis that the altered protein signature found 
in T2DM patients is associated with dysregulation at the 
miRNA level, and further to lay the foundation for novel 
hypotheses addressing the increased CVD risk of T2DM 
patients.
Methods
Artery tissue
The Odense Artery Biobank comprises internal thoracic 
arteries (ITAs) collected from patients undergoing coro-
nary artery by-pass grafting (CABG) at Odense Univer-
sity Hospital in Denmark since 2008. These arteries have 
been the foundation for several studies addressing vascu-
lar pathophysiology [11, 20–24].
RNA purification
RNA for microarray analysis was isolated from fresh 
frozen ITAs (from 18 T2DM- (10 of which were sub-
ject to metformin treatment) and 30 non-diabetes mel-
litus (non-DM) patients) using NORGEN Total RNA 
Purification Kit (#17200,37500, Norgen Biotek Corpora-
tion), while RNA for quantitative polymerase chain reac-
tion (qPCR) analysis was isolated from formalin-fixated 
paraffin-embedded (FFPE) ITAs [from 26 T2DM- (15 of 
which were subject to metformin treatment) and 26 non-
DM patients; four sections of 20 µm from each patient] 
using NORGEN FFPE RNA Purification kit (#25300, 
Norgen Biotek Corporation). FFPE sections was obtained 
from FFPE tissue blocks previously used to determine 
differential basement membrane protein expression [8]. 
To allow for normalization of sample-to-sample varia-
tion in RNA isolation from FFPE sections and reverse 
transcription (RT) efficiency, 5 fmol synthetic Arabidop-
sis thaliana miR-159a (ath-miR-159a) was added to each 
sample along with buffer RL when using the NORGEN 
FFPE RNA Purification kit.
MicroRNA microarray
All experiments and analyses were conducted at Exiqon 
Services, Denmark. Total RNA was quantified via 
absorbance spectrophotometry in a NanoDrop 8000 
(Thermo Scientific, Wilmington, DE, USA) and veri-
fied by an Agilent 2100 Bioanalyzer profile. 750 ng total 
RNA from sample and reference was labeled with Hy3™ 
and Hy5™ fluorescent label, respectively, using the miR-
CURY LNA™ microRNA Hi-Power Labeling Kit, Hy3™/
Hy5™ (Exiqon, Denmark). The Hy3™-labeled samples 
and a Hy5™-labeled reference RNA sample were mixed 
pair-wise and hybridized to the miRCURY LNA™ micro-
RNA Array 7th Gen (Exiqon, Denmark), which contains 
capture probes targeting all microRNAs for human (2042 
miRNAs), mouse (1281 miRNAs) and rat (723 miRNAs) 
registered in the miRBASE 18.0. The hybridization was 
performed according to the miRCURY LNA™ microRNA 
Array instruction manual using a Tecan HS4800TM 
hybridization station (Tecan, Austria). One slide 
cracked in the hybridization station so no profiling data 
was obtained for this sample (resulting in 48 success-
ful samples). After hybridization the microarray slides 
were scanned and stored in an ozone free environment 
(ozone level below 2.0  ppb) in order to prevent poten-
tial bleaching of the fluorescent dyes. The miRCURY 
LNA™ microRNA Array slides were scanned using the 
Agilent G2565BA Microarray Scanner System (Agilent 
Technologies, Inc., USA) and the image analysis was car-
ried out using the ImaGene 9.0 software (BioDiscovery, 
Inc., USA). The quantified signals were background cor-
rected (Normexp with offset value 10 [25]) and normal-
ized using quantile normalization method, which was 
found to produce the best between-slide normalization 
to minimize the intensity-dependent differences between 
the samples. The threshold for detection was calculated 
for each individual microarray slide as 1.2 times the 25th 
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percentile of the overall signal intensity of the slide. MiR-
NAs with intensities above threshold in less than 20% 
of the samples were removed from the final dataset. By 
this filtering procedure, 677 probes were included in the 
expression analysis.
In Additional file  1, non-annotated human miRPlus 
miRNAs are predicted miRNA sequences derived from 
Exiqon’s database of proprietary material, database min-
ing, and publications.
Quantitative polymerase chain reaction
12 miRNAs were selected (Table 2) for quantification in 
FFPE ITA samples. Total RNA was quantified via absorb-
ance spectrophotometry in a NanoDrop 8000 (Thermo 
Scientific, Wilmington, DE, USA) and miRNA expression 
was measured by qPCR using TaqMan microRNA assays 
(Life Technologies). Total RNA was converted to cDNA 
using the TaqMan MicroRNA Reverse Transcription Kit 
and Megaplex stem-loop RT primers for Human Pool 
A and B (Life Technologies) according to the manufac-
turer’s instructions for low sample input (LSI). For each 
sample an equal amount of RNA (12  ng) was used as 
input for each RT and two RT reactions were established; 
one with Pool A and one with Pool B Megaplex RT prim-
ers. Each RT reaction had a final volume of 7.5 µL.
Pre-amplification was performed using Megaplex 
PreAmp primers for Human Pool A or Pool B (Life Tech-
nologies) and TaqMan PreAmp Mastermix (Life Tech-
nologies) according to the manufacturer’s instructions for 
LSI. PreAmp reactions had a final volume of 25 µL and 
contained 2.5 µL RT-product. Thermal cycling conditions 
were as follows: 95  °C for 10  min, 55  °C for 2  min, and 
72  °C for 2 min, followed by 12 cycles of 95  °C for 15  s 
and 60 °C for 4 min. Final inactivation was performed at 
99.9  °C for 10 min. PreAmp-products were diluted 1:10 
in 0.1× TE buffer (pH 8.0).
For the qPCR step 1  µL of diluted PreAmp-product 
was mixed with TaqMan Universal PCR Master Mix 
II (2×) and TaqMan miRNA assay (20×) in a final vol-
ume of 10 µL. qPCR was performed on a ViiA7 real-time 
instrument (Applied Biosystems, Foster City, CA, USA) 
and samples were run in triplicate. Thermal cycling con-
ditions were as follows: 95 °C for 10 min followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min.
The ViiA7 Real-Time qPCR Analysis Software was 
used to obtain quantification cycle (Cq)-values, which 
were exported to the  qBasePLUS software (Biogazelle, 
NV, Belgium) for relative quantification. Cq-values were 
converted to relative quantities using the method of 
 qBasePLUS, which is a modification of the classic delta–
delta-Cq method [26]. The modification takes multiple 
reference genes and gene specific amplification efficien-
cies into account, as well as the error on the estimated 
amplification efficiency [26]. Briefly, Cq-values are first 
converted into relative quantities based on the gene spe-
cific amplification efficiency. Normalization is then per-
formed by dividing the relative quantities by a sample 
specific normalization factor, which is calculated by tak-
ing the geometric mean of the relative quantities of the 
reference genes as described by Hellemans et al. [26].
In order to measure miRNA levels samples were spread 
across two different runs for each miRNA and data was 
corrected for inter-run variation using inter-run calibra-
tion. For each measured miRNA two samples (inter-run 
calibrators) were measured in both of the different runs, 
in addition to the other samples that were spread across 
the runs. In the  qBasePLUS software the results for the 
inter-run calibrators were used to quantify and correct 
for inter-run variation by determine a calibration fac-
tor for every miRNA-run combination [26]. Normaliza-
tion was performed using equal amounts of total RNA 
for each sample and by normalizing to the synthetic 
miRNA ath-miR-159a using the  qBasePLUS software [26]. 
In addition miRNA data was also normalized using ref-
erence genes. First, putative reference genes were evalu-
ated using geNorm [27] as an implementation of the 
 qBasePLUS software. Three putative reference genes for 
normalization were evaluated for both Pool A and Pool 
B miRNA data using geNorm. Reference genes were 
selected based on the average expression stability value 
M. Based on this, two miRNAs (hsa-miR-103a-3p and 
hsa-miR-27a-3p) were selected as reference genes for 
Pool A miRNA data, while one miRNA (hsa-miR-942-5p) 
and one small RNA (U6 rRNA) were selected as refer-
ence genes for Pool B miRNA data. Pool A and Pool B 
miRNA data were normalized separately. When using 
endogenous controls for normalization of the miRNA 
data all P-values given in Table 2 were above 0.05 (data 
not shown). Hence, fine consistency exist between data 
normalized using two different normalization strategies.
Statistics
For patient characteristics, Student’s t-tests or Fisher’s 
exact tests were performed when appropriate.
For explorative analysis, Student’s t-tests were per-
formed for each of the 677 probes in each of the three 
two-group comparisons (T2DM patients vs. non-DM 
patients; non-metformin treated T2DM patients vs. 
non-DM patients; metformin treated T2DM patients vs. 
non-metformin treated T2DM patients) followed by false 
discovery rate (FDR) correction of multiple testing.
For the targeted analysis, Student’s t-tests were used 
to test for differential expression in the three two-group 
comparisons. Intergroup differences accompanied by 
Bonferroni-corrected P-values below 0.004 [0.05/12 (12 
Page 4 of 10Steffensen et al. Cardiovasc Diabetol  (2018) 17:72 
being the number of tests performed)] were considered 
statistically significant.
Results
Tissue and study subjects
One hundred ITAs systematically collected in the 
Odense Artery Biobank over a 9-year period from CABG 
were analyzed in this study. The ITAs used in this study 
were all free of histologically apparent lesions, i.e. inti-
mal thickening and atherosclerosis. Although morpho-
logically indistinguishable between T2DM and non-DM 
patients (Fig. 1), several molecular differences have been 
identified between these groups within this tissue [8, 10, 
11].
T2DM and non-DM patients used in this study were 
matched on age at surgery, sex, plasma cholesterol, 
plasma creatinine, blood pressure and statin treatment. 
T2DM and non-DM patients in study group 1 (microar-
ray/explorative analysis) differed on glycated hemoglobin 
(HbA1c) and body mass index (BMI), while in study 
group 2 (qPCR/targeted analysis), these groups differed 
on HbA1c, high-density lipoprotein (HDL) and triglycer-
ides (TAG) (Table 1).
Explorative analysis
To screen for vascular miRNAs dysregulated in the set-
ting of T2DM, RNA was purified from fresh frozen ITAs 
and analyzed by miRNA microarray. 677 probes were 
included in the analysis based on pre-defined criteria 
for probe signal intensity (see “Methods” section). Prior 
to correction for multiple testing, a single miRNA (miR-
142-3p) was differentially expressed between T2DM and 
non-DM patients. Three miRNAs (miRPlus-B1114, miR-
5584-3p, and miR-5006-3p) were differentially expressed 
comparing non-metformin-treated T2DM- and non-DM 
patients, and seven miRNAs (miR-491-3p, miRPlus-
A1086, miR-193b-3p, miR-3935, miR-1252-5p, miRPlus-
B1114, and miR-5681b) were differentially expressed 
between metformin-treated and non-metformin-treated 
T2DM patients (Fig.  2). However, no miRNAs were 
found to be affected post FDR correction.
Targeted analysis
We then performed an independent experiment using a 
targeted qPCR-based approach. A panel of 12 miRNAs 
was selected (Table 2). This panel included miR-221-5p 
and miR-222-5p which were reported to be affected 
by diabetes in a similar setting by others [28]. We also 
500 um
500 um
250 um
250 um
T2
D
M
N
on
-D
M
Fig. 1 Representative internal thoracic arteries (ITAs) from T2DM and non-DM patients. Weigert stained cross-sections of internal thoracic arteries 
(ITAs) show lesion-free, homogenous arteries, which are indistinguishable between T2DM and non-DM patients
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Table 1 Clinical characteristics for each group study
Study group 1 (explorative analysis)
T2DM
n = 18
Non-DM
n = 30
P T2DM (− Met)
n = 8
Non-DM
n = 30
P T2DM (+ Met)
n = 10
T2DM (− Met)
n = 8
P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age at surgery, 
years
66.61 ± 7.51 63.60 ± 8.98 0.219 67.13 ± 8.63 63.60 ± 8.98 0.330 66.20 ± 6.94 67.13 ± 8.63 0.809
HbA1c, % 6.94 ± 1.21 5.74 ± 0.38 0.002 7.37 ± 1.52 5.74 ± 0.38 0.029 6.56 ± 0.76 7.37 ± 1.52 0.236
HbA1c, mmol/
mol
52.28 ± 13.07 39.21 ± 4.08 0.002 56.93 ± 16.41 39.21 ± 4.08 0.029 48.21 ± 8.36 56.93 ± 16.41 0.238
Cholesterol, 
mmol/L
4.19 ± 1.11 4.45 ± 1.16 0.486 4.27 ± 1.16 4.45 ± 1.16 0.721 4.11 ± 1.14 4.27 ± 1.16 0.803
LDL, mmol/L 2.31 ± 0.70 2.61 ± 1.01 0.267 2.41 ± 0.76 2.61 ± 1.01 0.571 2.21 ± 0.68 2.41 ± 0.76 0.614
HDL, mmol/L 1.16 ± 0.38 1.21 ± 0.33 0.684 1.01 ± 0.24 1.21 ± 0.33 0.101 1.30 ± 0.46 1.01 ± 0.24 0.168
Triglycerides, 
mmol/L
1.88 ± 1.21 1.45 ± 0.63 0.210 2.23 ± 1.54 1.45 ± 0.63 0.234 1.58 ± 0.81 2.23 ± 1.54 0.344
Creatinine, 
µmol/L
83.72 ± 15.42 85.70 ± 13.14 0.653 76.88 ± 11.22 85.70 ± 13.14 0.080 89.20 ± 16.62 76.88 ± 11.22 0.080
BMI, kg/m2 29.98 ± 3.06 27.26 ± 3.77 0.010 29.24 ± 2.57 27.26 ± 3.77 0.104 30.57 ± 3.42 29.24 ± 2.57 0.360
SBP, mm Hg 134.22 ± 19.47 138.42 ± 22.13 0.510 141.38 ± 22.36 138.42 ± 22.13 0.749 128.50 ± 15.66 141.38 ± 22.36 0.192
DBP, mm Hg 75.06 ± 11.61 77.70 ± 12.78 0.476 80.00 ± 14.63 77.70 ± 12.78 0.697 71.10 ± 7.02 80.00 ± 14.63 0.146
Male sex, % 100 100 … 100 100 … 100 100 …
Statins, n 18 30 … 8 30 … 10 8 …
Antihyperten-
sives, n
17 26 0.637 7 26 1.000 10 7 0.444
Insulins, n 6 0 0.002 4 0 < 0.001 2 4 0.321
Oral antidiabetic 
agents, n
12 0 < 0.001 2 0 0.040 10 2 0.002
Study group 2 (targeted analysis)
T2DM
n = 26
Non-DM
n = 26
P T2DM 
(− Met)
n = 11
Non-DM
n = 26
P T2DM 
(+ Met)
n = 15
T2DM 
(− Met)
n = 11
P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age at surgery, 
years
67.84 ± 4.83 68.99 ± 5.24 0.410 67.35 ± 4.21 68.99 ± 5.24 0.367 68.25 ± 5.35 67.35 ± 4.21 0.670
HbA1c, % 7.11 ± 1.11 5.60 ± 0.37 < 0.001 7.41 ± 1.39 5.60 ± 0.37 < 0.001 6.84 ± 0.75 7.41 ± 1.39 0.231
HbA1c, mmol/
mol
54.24 ± 12.17 37.71 ± 4.03 < 0.001 57.48 ± 15.19 37.71 ± 4.03 < 0.001 51.28 ± 8.16 57.48 ± 15.19 0.230
Cholesterol, 
mmol/L
3.76 ± 1.04 4.20 ± 1.26 0.230 4.00 ± 1.32 4.20 ± 1.26 0.692 3.55 ± 0.68 4.00 ± 1.32 0.329
LDL, mmol/L 1.85 ± 0.69 2.33 ± 0.90 0.058 2.07 ± 0.87 2.33 ± 0.90 0.447 1.65 ± 0.42 2.07 ± 0.87 0.174
HDL, mmol/L 1.13 ± 0.24 1.41 ± 0.51 0.030 1.14 ± 0.25 1.41 ± 0.51 0.129 1.12 ± 0.25 1.14 ± 0.25 0.851
Triglycerides, 
mmol/L
1.90 ± 0.89 1.21 ± 0.35 0.002 1.89 ± 1.03 1.21 ± 0.35 0.011 1.91 ± 0.79 1.89 ± 1.03 0.960
Creatinine, 
µmol/L
96.12 ± 29.47 86.40 ± 16.93 0.160 95.64 ± 32.61 86.40 ± 16.93 0.269 96.47 ± 28.12 95.64 ± 32.61 0.945
BMI, kg/m2 28.66 ± 3.95 27.13 ± 3.69 0.150 27.21 ± 3.41 27.13 ± 3.69 0.949 29.73 ± 4.08 27.21 ± 3.41 0.110
SBP, mm Hg 141.12 ± 18.64 139.92 ± 19.79 0.820 138.82 ± 10.59 139.92 ± 19.79 0.863 142.80 ± 23.09 138.82 ± 10.59 0.601
DBP, mm Hg 74.92 ± 10.42 77.73 ± 10.71 0.340 75.73 ± 12.28 77.73 ± 10.71 0.621 74.33 ± 9.24 75.73 ± 12.28 0.744
Male sex, % 85 85 … 82 85 … 87 82 …
Statins, n 26 26 … 11 26 … 15 11 …
Antihyperten-
sives, n
21 13 0.040 8 13 0.285 13 8 0.620
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included miR-29a-3p and miR-29b-3p—the primary 
candidates to regulate the level of α1- and α2-chain of 
collagen IV [12–17]. Finally, we included eight miR-
NAs (miR-21-5p, miR-24-3p, miR-26a-5p, miR-182-3p, 
miR-145-5p, miR-132-3p, miR-212-3 and miR-1298-5p) 
previously demonstrated to be involved in phenotypic 
modulation of vascular smooth muscle cells [29–37], 
since these are the vast majority of cells in ITAs.
Important for the aim of our study, the RNA used for 
this analysis was obtained from sections of the same 
FFPE tissue that we used to document elevated levels of 
basement membrane proteins [8, 10].
Although most miRNAs were successfully quantified 
in all samples, we failed to detect miR-182-3p in 25 of 
52 samples and miR-221-5p in all of the 52 samples. 
We assume this is due to low abundance since both 
miR-182-3p- and miR-221-5p were excluded from the 
microarray analysis, because of low signal intensity, 
however technical issues could potentially also be an 
issue.
Nominal p-values below 0.05 were found for several 
miRNAs in the intergroup comparisons: miR-222-5p 
and miR-1298-5p [T2DM (− Met) vs. non-DM], and 
miR-24-3p, miR-145-5p, miR-222-5p and miR-1298-5p 
[T2DM (+ Met) vs. T2DM (− Met)] (Table 2). However, 
following Bonferroni correction of multiple testing no 
significant differences were observed. An interesting 
pattern is observed for miR-222-5p and miR1298-5p as 
expression is reduced in non-metformin treated T2DM 
patients as compared to both non-DM patients and 
metformin-treated patients, suggesting that metformin 
treatment counteracts the effect of T2DM. However, 
the same trends were not seen in the microarray data 
(Additional file 1).
For each study group three comparisons of clinical data are made: T2DM vs. non-DM patients; non-metformin-treated T2DM (− Met) vs. non-DM patients; and non-
metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met). Results are shown as mean ± SD, percentage (%) or number (n) as indicated
In study group 1, one slide cracked during the hybridization process. Since no miRNA expression data is available for this sample, the accompanying patient data is 
not included in the table
HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, BMI Body-mass index, SBP systolic blood pressure, DBP diastolic blood 
pressure
Table 1 (continued)
Study group 2 (targeted analysis)
T2DM
n = 26
Non-DM
n = 26
P T2DM 
(− Met)
n = 11
Non-DM
n = 26
P T2DM 
(+ Met)
n = 15
T2DM 
(− Met)
n = 11
P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Insulins, n 6 0 0.023 3 0 0.021 3 3 0.218
Oral antidiabetic 
agents, n
19 0 < 0.001 4 0 0.005 15 4 < 0.001
0.05
-1.0 -0.5 0.0 0.5 1.0
0.0
0.2
0.4
0.6
0.8
1.0
-1.0 -0.5 0.0 0.5 1.0
0.0
0.2
0.4
0.6
0.8
1.0
-1.0 -0.5 0.0 0.5 1.0
0.0
0.2
0.4
0.6
0.8
1.0
P
logFC logFC logFC
0.05 0.05
T2DM vs. Non-DM T2DM (- Met) vs. Non-DM T2DM (+ Met) vs. T2DM (- Met)
Fig. 2 MiRNA expression profiling in arterial samples from T2DM and non-DM patients. MiRNA profiling was performed by microarray analysis. Data 
is represented as volcano plots for the following comparisons: T2DM vs. non-DM patients (reference group); non-metformin-treated T2DM (− Met) 
vs. non-DM patients (reference group); and non-metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met) (reference group). 
MiRNAs with P values less that 0.05 (prior to false discovery rate (FDR) correction of multiple testing) are represented as circles. The x-axis shows the 
log2 fold-change in miRNA expression and y-axis shows the P value
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Discussion
To the best of our knowledge, this is the first study to 
assess the influence of diabetes on macrovascular miRNA 
expression using an explorative approach. Unexpectedly, 
we were unable to detect any vascular miRNAs for which 
the expression level is affected by either T2DM status 
or metformin-treatment. Moreover, we were not able 
to detect differential expression of 12 selected miRNAs 
using a targeted qPCR-based approach in an independ-
ent study group, which we previously have used to dem-
onstrate distinct diabetes-induced changes at the protein 
level [8].
This finding is not consistent with a previous report by 
Coleman et al. showing a more than twofold elevation in 
the expression of miR-221-5p and miR-222-5p in ITAs 
from non-metformin-treated T2DM patients as com-
pared to both non-DM patients and metformin-treated 
T2DM patients [28]. miR-221-5p was excluded from the 
microarray analysis as it did not reach the threshold of 
signal intensity, and was not detectable by qPCR in any 
sample of study group 2. miR-222-5p was detected in 
both analyses, yet we found no significant effect of T2DM 
or metformin-treatment. The explanation underlying this 
discrepancy is unclear, however, while study populations 
are comparable in size, differences do exist. In Coleman 
et al., the T2DM patients that were not treated with met-
formin are obese (BMI: 34.8 ± 1.4), while the equivalent 
group in both our study groups are merely overweight 
[BMI: 29.2 ± 2.6 (Study group 1) and 27.2 ± 3.4 (Study 
group 2)], which may explain dissimilarities, since obesity 
is closely related to epigenetic alterations [38]. Impor-
tantly, technical variability caused by differences in tis-
sue preparation, RNA purification, reverse transcription, 
qPCR methodology and/or normalization strategies may 
contribute to the observed differences between the study 
by Coleman et al., and this study.
Evaluation of changes induced specifically by diabetes 
(being hyperglycemia or vascular insulin resistance) on 
vascular cells and tissue that might prime subsequent 
pathological mechanisms necessitates analysis of non-
diseased artery tissue. Our study focus on such putative 
alterations and is based on analysis of ITAs devoid of 
lesions. The microRNAome is strongly affected by artery 
lesions such as intimal hyperplasia or atherosclerosis 
[39, 40] and the presence of such lesions could poten-
tially outweigh the influence of diabetes on vascular cells. 
Moreover, varying degree of disease progression between 
samples would introduce heterogeneity and intragroup 
variability, which reduce the ability to detect intergroup 
differences. As we base our study on non-lesional arteries 
we do not address potential effects of diabetes on miRNA 
expression after lesion initiation. Although difficult to 
detect due to the reasons stated above, hyperglycemia 
or vascular insulin resistance might have an effect on 
miRNA expression of inflammatory cells or phenotypi-
cally modulated artery cells. Also, diabetes may affect 
miRNA expression in the presence of other pathological 
stimuli like inflammation. Since the purpose of our study 
is to identify diabetes-induced vascular changes that pre-
cede and prime pathological processes, it is a limitation 
that we use an artery that is lesion resistant. However, 
vascular alterations induced by e.g. hyperglycemia pre-
sumably affects all arteries similarly, while the principal 
determinant of the susceptibility to atherosclerosis is 
local hemodynamics [41].
After an initial explorative analysis, we focus on a panel 
of 12 miRNAs in the targeted analysis. The 12 miRNAs 
selected for this analysis have previously been reported 
to be regulated in the setting of diabetes, to be known 
regulators of collagen IV expression, or to affect pheno-
typic modulation of vascular smooth muscle cells. Not 
considering miRNAs implicated in other vascular disease 
processes such as inflammation [42] or other diabetes-
related conditions [43–45] in the targeted analysis is a 
limitation in our study. Moreover, several factors and 
pathways are known to be associated to vascular com-
plications in diabetic patients, and since we do not have 
comprehensive data whether our patients display these 
characteristics, we cannot exclude that differences in 
such factors may have influenced our results.
We previously identified elevated levels of a distinct 
group of proteins associated with basement membranes 
in non-lesional arteries of T2DM patients. The under-
lying mechanisms remain elusive, although it does not 
appear to be associated with altered expression of the 
genes encoding these proteins. In this study we sought 
to identify whether miRNA expression was affected by 
T2DM status, and if such regulation could explain our 
previous observations. As we were unable to detect dif-
ferential expression of miRNAs between T2DM and 
non-DM patients, we suggest that other mechanisms 
of regulation such as decreased protein degradation in 
diabetics underlie our previous findings.
Conclusions
Our data suggest that alternatives to microRNA dys-
regulation underlie T2DM-associated protein changes 
in non-atherosclerotic arteries.
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